Plan B Draws Criticism During Von Eschenbach Confirmation Hearing
This article was originally published in The Tan Sheet
Executive Summary
FDA's recent request to meet with Barr Labs about the proposed OTC sale of Plan B has done little to quell criticisms from Senate Democrats concerning the agency's extensive delays in issuing a decision on the Rx-to-OTC switch application